

Correspondance

Patient compliance with drug therapy for diabetic nephropathy

William Clark and colleagues were clearly sensitive to the effects of patient compliance in their study of the cost-effectiveness of angiotensin-converting-enzyme (ACE) inhibitor therapy for diabetic nephropathy.¹ This highlights 3 important assumptions regarding compliance that require further clarification.

First, it was assumed that noncompliers lose renal function at the same rate as patients in the placebo arm of a diabetic nephropathy trial comparing the effects of ACE inhibitors and placebo.² It would seem unlikely that patients taking up to 80% of their ACE inhibitor (the definition Clark and colleagues offered for noncompliance) would lose renal function at the same rate as those taking none. The rate at which noncompliers lose renal function should have been subjected to sensitivity analysis.

Second, the authors based their analysis on the results of a patient-interview study³ in which 34% of patients stated cost as the primary barrier to compliance. To suggest that 34% of patients would be noncompliant for this reason is a major assumption. A recent observational study of persistence with antihypertensive therapy suggested that the relationship between drug cost and compliance was less clear.⁴ The more expensive ACE inhibitors were in fact associated with higher persistence rates. Thus, when one is evaluating the implications of noncompliance, factors other than drug costs must not be ignored.

Finally, provincial drug coverage may not have had as much impact as assumed because a proportion of patients already have the cost of their medications covered through private insurance. Before ACE inhibitor coverage becomes standard practice, we

propose that the effect on compliance of providing medications free at the point of delivery should be more thoroughly assessed. If such studies confirm that compliance improves significantly, then consideration could, in fact, be given to developing a national pharmacare program, whereby cost-effective medications, such as ACE inhibitors for diabetic nephropathy, would be provided free to all Canadians.

Dyfrig Hughes

Prescribing Research Group
University of Liverpool
Liverpool, UK

Braden Manns

Internist
Calgary, Alta.

Competing interests: None declared.

References

1. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. *CMAJ* 2000;162(2):195-8.
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-enzyme inhibition on diabetic nephropathy. *N Engl J Med* 1993;329:1456-62.
3. Brand FN, Smith RT, Brand PA. Effect of economic barriers to medical care on patients' non-compliance. *Public Health Rep* 1977;92:72-8.
4. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. *CMAJ* 1999; 160(1):41-6.

[Two of the authors respond:]

Dyfrig Hughes and Braden Manns suggest that there are 3 important assumptions regarding compliance that require further clarification in our decision and cost-utility analysis.¹

First, we assumed that noncompliers lose renal function at the same rate as patients in the placebo arm of a diabetic nephropathy trial.² We selected 80% adherence as the threshold required for antihypertensive drug effect on the basis of studies³⁻⁶ we referenced in our article.¹ However, some degree

of renoprotection may still occur at adherence levels below 80%, as the renoprotective effects of the drug therapy may be independent of the blood pressure effects in this particular disease. Therefore, we do concur that a sensitivity analysis could have been carried out.

Second, Hughes and Manns question whether cost really is the primary barrier for drug adherence for 34% of patients. This assumption is based on a Canadian study that indicated that 34% of the compliance failure was due to cost, representing 17% of patients.⁷ We indicated in our article that this was a conservative estimate, as price elasticity has been demonstrated to be as high as 64% in a large randomized controlled study and a very large population study.^{8,9} We would contend that the figure we used describing the relationship between drug cost and adherence is conservative. Hughes and Manns also indicate that the relationship was less clear in view of a study by Caro and colleagues that looked at patients in Saskatchewan between 1989 and 1994.¹⁰ They may not be aware that in Saskatchewan during that time period there was a fairly comprehensive pharmacare program, which might explain variations between expensive and inexpensive antihypertensive agents.¹¹ However, we agree that factors other than drug costs must not be ignored when evaluating the implications of noncompliance.

Finally, we feel that our assumption concerning the proportion of patients already being covered through provincial or private insurance is valid. We concur with Hughes and Manns that the effect on adherence of providing medications free at the point of delivery should be more thoroughly assessed. We also hope that if such studies are undertaken and do show significant improvements in adherence, there would be consideration to developing a national pharmacare program whereby cost-effective medica-

tions such as ACE inhibitors for diabetic nephropathy would be provided free to all Canadians.

William F. Clark
Division of Nephrology
London Health Sciences Centre
London, Ont.
Lorie Forwell
Department of Physiotherapy
University of Western Ontario
London, Ont.

Competing interests: See original article.¹

References

1. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. *CMAJ* 2000;162(2):195-8.
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-enzyme inhibition on diabetic nephropathy. *N Engl J Med* 1993;329:1456-62.
3. Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: Haynes RB, Taylor DW, Sackett DL, editors. *Compliance in health care*. Baltimore: Johns Hopkins University Press; 1979. p. 11-23.
4. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. *Ann Intern Med* 1984;100:258-68.
5. Gibaldi M. Failure to comply: a therapeutic dilemma and the bane of clinical trials. *J Clin Pharmacol* 1996;36:674-82.
6. McKenney JM, Munroe WP, Wright JT. Impact of an electronic medication compliance aid on long-term blood pressure control. *J Clin Pharmacol* 1992;32:277-83.
7. Brand FN, Smith RT, Brand PA. Effect of economic barriers to medical care on patients' non-compliance. *Public Health Rep* 1977;92:72-8.
8. Leibowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost-sharing. *Soc Sci Med* 1985;21:1063-9.
9. O'Brien B. The effect of patient charges on the utilisation of prescription medicines. *J Health Econ* 1989;8:109-32.
10. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. *CMAJ* 1999;160(1):41-6.
11. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. *CMAJ* 1999;160(1):31-7.

Access to the morning-after pill in BC

The primary goal of the BC emergency postcoital contraception initiative, which was discussed in a recent *CMAJ* article,¹ is to increase the availability of this important option for women's reproductive health. The

resolution of the Society of Obstetricians and Gynaecologists of Canada calling for increased access to emergency postcoital contraception prompted the College of Pharmacists of BC to consider the situation in our province. It was clear that more work was needed to inform women about emergency postcoital contraception and to make it more accessible. Pharmacists can play a vital role in making this happen because of their knowledge of drug therapy and their availability. The threats and violence against physicians who perform abortions serve as a reminder that extreme emotions are associated with issues of reproductive choice and that much more needs to be done to prevent unintended pregnancies.

The *CMAJ* article states that BC will be making Preven a schedule II medication.¹ The hormones for emergency contraception are classed as prescription drugs at the federal level. The provinces cannot change the classification of a drug from prescription to nonprescription by placing it in schedule II. Provincial authorities can, however, explore avenues for permitting pharmacists to dispense a prescription drug without a physician's prescription. One mechanism may be to work in collaboration with a physician. Another option is to create a pharmacists' prescribing schedule. The College of Pharmacists of BC has submitted a resolution to the provincial government calling for the creation of schedule IV. The only drugs in the schedule would be the hormones for emergency contraception. By approving schedule IV, the provincial government would grant pharmacists independent prescribing authority for these products only.

Brenda Osmond
Deputy Registrar
College of Pharmacists of BC
Vancouver, BC

Reference

1. Sibbald B. Despite some opposition, BC pharmacists to dispense morning-after pill without prescription. *CMAJ* 2000;162(6):876-7.

What exactly are we treating with the morning-after pill?¹ The absence of any medical facts is obvious. The morning-after pill is really an abortion pill. The joining of the sperm and the ovum in the fallopian tubes creates the beginning of a life. All of the DNA that we will require for the rest of our lives is present at that first moment. After that, only the amount of dependency on our parents decreases with time. The morning-after pill prevents the implantation of a unique human individual, tiny but unique and genetically complete.

Is it any wonder that some pharmacists are objecting on ethical grounds? They don't want to see themselves as abortionists. Who can blame them? Let's stick to the facts. Rhetoric about providing a service and reducing violence against physicians obscures the fact that this pill is ending a unique individual's life.

William D. Gutowski
Psychiatrist
Chilliwack, BC

Reference

1. Sibbald B. Despite some opposition, BC pharmacists to dispense morning-after pill without prescription. *CMAJ* 2000;162(6):876-7.

Managing hypertension in patients with renal disease and diabetes

Congratulate the authors of the 1999 Canadian recommendations for the management of hypertension¹ for their diligent work, but question the recommendations regarding hypertensive patients with diabetic and nondiabetic renal disease. Ample evidence exists to support the use of angiotensin-converting-enzyme (ACE) inhibitors as first-line agents in both of these circumstances, but the selection of dihydropyridine calcium-channel blockers as an alternative therapy for nondiabetic renal disease and the lack of a recommendation for the use of nondihydropyridines in diabetic nephropathy are questionable.

A number of well-designed studies

have demonstrated that the reduction of proteinuria and preservation of renal function by nondihydropyridines, particularly verapamil, is similar to that by ACE inhibitors in diabetic nephropathy.²⁻⁴ These studies further indicate that the reduction of proteinuria by nondihydropyridines is additive to the effect of ACE inhibitors.

In contrast, studies using dihydropyridines have failed to demonstrate a benefit with regard to proteinuria or renal function unless systolic blood pressure is reduced below 110 mm Hg.⁵ Furthermore, several trials have demonstrated a renal hazard associated with the use of dihydropyridines in diabetic nephropathy and other situations. Isradipine was associated with a 50% increase in proteinuria in African Americans with diabetic nephropathy.⁶ In the PRAISE trial 7.7% of subjects randomized to receive amlodipine had worsening renal function compared with 3.6% in the placebo group.⁷

The guidelines cite studies by Bianchi and colleagues and Zucchelli and colleagues in support of the recommendation for the use of dihydropyridines in nondiabetic renal failure.^{8,9} Although in these 2 studies an ACE inhibitor and a dihydropyridine produced similar changes in renal function, the effects with respect to proteinuria and renal death were significantly better with the ACE inhibitor.

Loss of renal autoregulation has been suggested as one mechanism for the unfavourable effects seen with the dihydropyridines.¹⁰ Because nondihy-

dropyridine calcium-channel blockers do not impair renal autoregulation,¹¹ have a favourable effect on glomerular permeability and have been demonstrated to be renal protective in clinical studies previously cited, they may be a better choice as an alternative therapy in diabetic and nondiabetic nephropathy and perhaps in all diabetic patients with hypertension.

Alan Bell
Family physician
Downsview, Ont.

Competing interests: Dr. Bell serves as a medical consultant to Searle Canada; he has received speaker fees and travel assistance grants.

References

1. Feldman RD, Campbell N, Laroche P, Bolli P, Burgess ED, Carruthers SG, et al, for the Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. 1999 Canadian recommendations for the management of hypertension. *CMAJ* 1999;161(12 Suppl):S1-22.
2. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. *Kidney Int* 1998;54:1283-9.
3. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. *Kidney Int* 1992;41:912-9.
4. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. *Kidney Int* 1996;50:1641-50.
5. Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by calcium-channel blockers. *Nephrol Dial Transplant* 1997;12:2244-50.
6. Guasch A, Parham M, Zayas CF, Campbell O, Nzerue C, Macon E. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. *J Am Soc Nephrol* 1997;8:793-8.
7. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. *N Engl J Med* 1996;335:1107-14.
8. Bianchi S, Bigazzi R, Baldari G, Campese VM. Long-term effects on enalapril and nifedipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up. *Am J Nephrol* 1991;11:131-7.
9. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. *Kidney Int* 1992;42:452-8.
10. Perna A, Remuzzi G. Abnormal permeability to proteins and glomerular lesions: a meta-analysis of experimental and human studies. *Am J Kidney Dis* 1996;27:34-41.
11. Maki DD, Ma JZ, Louis TA, Kasiske BL. Effects of antihypertensive agents on the kidney. *Arch Intern Med* 1995;155:1073-82.

The authors of the 1999 Canadian recommendations for the management of hypertension state that "hypertension in people with diabetes should be treated to obtain target blood pressure lower than 130/80 mm Hg."¹ This grade C recommendation is supported by evidence from the HOT² and UKPDS 38³ studies insofar as the diastolic target is concerned. However, we question the systolic target of 130 mm Hg given our review of the evidence from these 2 studies.

In the HOT study, the mean systolic blood pressure achieved by the group randomized to a diastolic target of < 80 mm Hg was 139.7 mm Hg. In the UKPDS 38 study, the mean systolic blood pressure achieved in the group randomized to "tight" blood pressure control was 144 mm Hg. Therefore, the evidence with regard to the systolic target for control of blood pressure in diabetic patients with hypertension points to 140 mm Hg rather than 130 mm Hg less.

The high prevalence of systolic blood pressures in the range of 130 to 140 mm Hg would mandate additional treatment for a large number of people if the Canadian guidelines were to be closely followed. Of note, the British Hypertension Society recommends that clinicians attempt to achieve a target of less than 140 mm Hg systolic blood pressure in hypertensive patients with type II diabetes.⁴ Is there additional evidence

Submitting letters

Letters may be submitted by mail, courier, email or fax. They must be signed by all authors and limited to 300 words in length. Letters that refer to articles must be received within 2 months of the publication of the article. *CMAJ* corresponds only with the authors of accepted letters. Letters are subject to editing and abridgement.

Note to email users

Email should be addressed to pubs@cma.ca and should indicate "Letter to the editor of *CMAJ*" in the subject line. A signed copy must be sent subsequently to *CMAJ* by fax or regular mail. Accepted letters sent by email appear in the Readers' Forum of *eCMAJ* (www.cma.ca/cmaj) promptly, and are published in a subsequent issue of the journal.

that led the authors to recommend a lower systolic target of 130 mm Hg?

Roland Grad

Department of Family Medicine
McGill University
Montreal, Que.

Stephen Hanley

Division of Clinical Epidemiology
Royal Victoria Hospital
Montreal, Que.

References

1. Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG, et al, for the Task Force for the Development of the 1999 *Canadian Recommendations for the Management of Hypertension*. 1999 Canadian recommendations for the management of hypertension. *CMAJ* 1999;161(12 Suppl):S1-22.
2. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. *Lancet* 1998;351:1755-62.
3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). *BMJ* 1998;7160:703-13.
4. Ramsay L, Williams B, Johnston G, MacGregor G, Poston L, Potter J, et al. Guidelines for management of hypertension: report of the Third Working Party of the British Hypertension Society. *J Hum Hypertens* 1999;13:569-92.

[Three of the authors respond:]

The correspondents have raised issues that were discussed during the course of our deliberations as we developed the recommendations.

Alan Bell questions the recommendations for treatment of patients with hypertension and renal disease especially regarding the role of nondihydropyridine calcium-channel blockers. Both in the treatment recommendations for hypertensive patients with renal disease as well as in the other recommendations, the primary basis for designating specific drugs as first-line therapy was effective reduction not only of blood pressure but also of the ultimate end points, namely rates of hypertension-related cardiovascular complications. Thus, the designation of ACE inhibitors as first-line therapy for hypertensive patients with renal disease was based on evidence that these drugs are effective in reducing the development of renal failure and

renal complications (beyond surrogate end points such as serum creatinine levels and proteinuria).¹ As Bell points out, advantages of nondihydropyridine calcium-channel blockers over dihydropyridine calcium-channel blockers may have been demonstrated in the context of measures of renal hemodynamics or proteinuria. However, the lack of head-to-head comparisons between ACE inhibitors and a nondihydropyridine calcium-channel blocker in "hard outcome" studies was the primary basis for not including them for this indication. With the conclusion of the recent spate of megatrials (including those assessing the effects of nondihydropyridine calcium-channel blockers on hard end points) a more definitive recommendation regarding this class of drugs in patients with renal insufficiency might be anticipated. Apropos, we have organized a process to continuously review the hypertension literature and update all of our hypertension recommendations. Recognizing the poor uptake of recommendations in clinical practice, we have also linked this recommendations development process to a formal implementation plan coordinated by Health Canada and including a range of stakeholders involved in hypertension management.

Roland Grad and Stephen Hanley raise a thoughtful question regarding the basis of the recommendation for a target blood pressure of less than 130/80 mm Hg for patients with hypertension and diabetes. As they identify, the main impetus for the target for diastolic blood pressure of < 80 mm Hg was the diabetic subgroup of the HOT study.² The grade C ascription was based on the diastolic blood pressure recommendation. The systolic target of 130 mm Hg was based on extrapolation from several sources. For the large subgroup of diabetic patients with some degree of nephropathy the target was based on studies of the greater population of patients with renal insufficiency for whom a mean arterial pressure target of 98 mm Hg (130/80 mm Hg) has been shown to

be associated with a reduced decline in glomerular filtration rate and renal complications.¹ Studies such as HOPE³ have reinforced the concept that for those patients at highest risk for atherosclerotic complications, blood pressure reduction even within the range nominally considered as normal (although epidemiologically associated with incremental risk for blood pressure related complications) would result in appreciable reductions in event rates. Parenthetically, this target for systolic blood pressure is consistent with that recommended by the World Health Organization – International Society of Hypertension⁴ as well as the US Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.⁵

Ross D. Feldman

University of Western Ontario
London, Ont.

Pierre Larochelle

Université de Montréal
Montreal, Que.

Norman Campbell

University of Calgary
Calgary, Alta.

for the Task Force for the Development
of the 1999 *Canadian Recommendations
for the Management of Hypertension*

Competing interests: See original article.¹

References

1. Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG, et al, for the Task Force for the Development of the 1999 *Canadian Recommendations for the Management of Hypertension*. 1999 Canadian recommendations for the management of hypertension. *CMAJ* 1999;161(12 Suppl):S1-22.
2. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet* 1998;351:1755-62.
3. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. *N Engl J Med* 2000;342:145-53.
4. Guidelines subcommittee. 1999 World Health Organization – International Society of Hypertension guidelines for the management of hypertension. *J Hypertens* 1999;17:151-83.
5. *The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure*. National Institutes of Health; 1997 Nov. Report no.: 98-4080.